Welcome to our dedicated page for Optimizerx news (Ticker: OPRX), a resource for investors and traders seeking the latest updates and insights on Optimizerx stock.
OptimizeRx Corporation (Nasdaq: OPRX) regularly issues news and updates about its healthcare technology platform, partnerships, and financial performance. Company press releases describe OptimizeRx as a healthcare technology company that helps life science brands reach and engage healthcare professionals (HCPs) and patients through AI-driven tools, point-of-care integrations, and proprietary audience data.
News items for OptimizeRx often cover collaborations with other data and media companies, such as integrations that connect its patented Micro-Neighborhood® audience data with external identity graphs or out-of-home advertising networks. These announcements explain how the company’s privacy-safe, deterministic audience cohorts are used to support omnichannel and direct-to-consumer campaigns, improve audience quality, and reduce audience loss during onboarding and activation.
Investors and observers will also find earnings releases and guidance updates among OptimizeRx news. These releases include discussions of revenue trends, profitability metrics, key performance indicators related to top pharmaceutical manufacturers, and commentary from management about the company’s progress toward its strategic objectives. Conference call announcements and investor conference participation are also common topics, providing details on how to access management’s discussions of quarterly and annual results.
Additional news highlights may include expansions of the company’s in-workflow point-of-care network through new or renewed agreements with electronic health record (EHR) vendors, e-prescribing platforms, and health systems access partners. Leadership updates and organizational changes are reported through current reports and associated press releases, outlining adjustments in executive roles and governance. For anyone following OPRX, this news page serves as a central source for official company communications on partnerships, technology developments, financial results, and corporate governance.
OptimizeRx (Nasdaq: OPRX) announced a data collaboration with Experian on January 7, 2026 to map OptimizeRx Micro-Neighborhood® audiences to Experian’s identity graph.
The integration enables deterministic onboarding, curated audience activation, and measurement designed to reduce audience loss and improve audience quality in privacy‑safe DTC healthcare marketing. Micro-Neighborhood® audiences target at ZIP+9 level across 35+ million U.S. micro-neighborhoods and are portable across major media channels for omnichannel activation and reporting.
OptimizeRx (Nasdaq: OPRX) announced four new partner agreements on Dec. 17, 2025 that expand its point-of-care (POC) network, deepen exclusivity with key platforms, and increase total National Provider Identifier reach. Together the additions and renewals raise OptimizeRx’s unique NPI reach by 37%.
Key deals include an exclusive multi-year agreement with a high-demand e-prescribing platform, a new point-of-discharge partnership that extends access when treatment plans are finalized, and multi-year renewals with two top-performing EHR/eRx partners that secure premium inventory and greater visibility into future channel revenue.
OptimizeRx (Nasdaq: OPRX) reported third-quarter 2025 results showing continued revenue and profitability growth. Q3 revenue was $26.1 million (+22% YoY) and gross profit was $17.5 million (+30% YoY). GAAP net income was $0.8 million ($0.04 per share) versus a loss in prior-year Q3; non-GAAP net income was $3.9 million ($0.20 per diluted share). Adjusted EBITDA rose to $5.1 million. Cash and short-term investments totaled $19.5 million at September 30, 2025. The company raised FY2025 guidance to $105–$109M revenue and $16–$19M adjusted EBITDA, and introduced FY2026 guidance of $118–$124M revenue and $19–$22M adjusted EBITDA.
OptimizeRx (Nasdaq: OPRX) will hold a conference call to discuss second quarter results for the period ended June 30, 2025. The call is scheduled for Thursday, August 7, 2025 at 4:30 p.m. ET (1:30 p.m. PT); a press release with financial results will be issued prior to the call.
Dial-in details include toll-free 1-844-825-9789, international 1-412-317-5180 and Conference ID 10200608. A webcast and a Call Me™ option are available. A replay will be available for 12 months via the company Investors page at http://www.optimizerx.com/investors.
OptimizeRx (Nasdaq: OPRX) will hold a third quarter 2025 conference call on Thursday, November 6, 2025 at 4:30 p.m. ET to discuss results for the quarter ended September 30, 2025. Management will host the call, followed by Q&A. Financial results will be released in a press release prior to the call.
Call access includes toll-free and international numbers, a Call Me link and a live webcast; a replay will be available for 12 months on the company investor website.
OptimizeRx (NASDAQ:OPRX), a healthcare technology solutions provider specializing in connecting life sciences companies with healthcare professionals and patients, has announced its participation in the 9th Annual Lake Street Capital Best Ideas Growth Conference. The event is scheduled for September 11, 2025, in New York, NY.
The company's management team will be available for meetings with institutional investors during the conference. Interested parties should contact their institutional representatives to arrange meetings.
OptimizeRx (NASDAQ: OPRX) has announced a strategic partnership with Lamar Advertising Company (NASDAQ: LAMR) to transform healthcare out-of-home (OOH) advertising. The collaboration integrates OptimizeRx's patented Micro-Neighborhood® Targeting (MNT) data with Lamar's nationwide advertising inventory, enabling precise targeting of healthcare audiences at the ZIP+4 level.
The partnership allows pharmaceutical and healthcare brands to leverage disease prevalence data for targeted OOH campaigns while maintaining privacy compliance. Key benefits include granular clinical geographic targeting, cost-effective scale compared to linear TV, nationwide reach across Lamar's network, measurable results, and strategic media mix integration.
OptimizeRx (NASDAQ:OPRX), a healthcare technology solutions provider, has announced significant leadership team advancements to accelerate its Rule of 40 strategy, which focuses on balancing growth with increased profitability.
Key appointments include: Ed Stelmakh as Chief Financial & Strategic Officer, Theresa Greco continuing as Chief Commercial Officer, Marion Odence-Ford as Chief Legal & Administrative Officer, Doug Besch as Chief Product & Technology Officer, Brendan Merrell as Chief Operating Officer, and Andy D'Silva as Chief Business Officer.
Under CEO Steve Silvestro's leadership, these organizational changes aim to enhance execution speed, strategic clarity, and drive the company's goal of achieving Rule of 40 in the next 2-3 years while transitioning to a recurring revenue model.
OptimizeRx (NASDAQ:OPRX) reported strong Q2 2025 financial results, with revenue increasing 55% year-over-year to $29.2 million. The company achieved significant improvements in profitability, posting a GAAP net income of $1.5 million ($0.08 per share) compared to a loss of $4.0 million in Q2 2024.
Gross profit rose 59% to $18.6 million, while Adjusted EBITDA reached $5.8 million, up from $0.5 million year-over-year. The company strengthened its financial position by paying down $4.5 million of principal on its outstanding term loan, $4.0 million above schedule.
Based on strong performance, OptimizeRx raised its full-year 2025 guidance, now expecting revenue between $104-108 million and Adjusted EBITDA between $14.5-17.5 million.
Paynela, an AI-driven healthcare financing company, has appointed William Febbo to its Board of Directors. Febbo, the former CEO of OptimizeRX (NASDAQ: OPRX) from 2016 to 2025, brings over 30 years of healthcare technology experience to the role.
During his tenure at OptimizeRX, Febbo transformed the company into a comprehensive omnichannel platform serving top pharmaceutical companies. He currently serves as Office of the Chairman at Oxbridge Health and on the Board of Directors at LifeMD. The appointment comes as Paynela, recently named a 2024 AWS Generative AI Trailblazer, has achieved a 320x increase in processing speed through its AI-driven healthcare data review platform.
FAQ
What is the current stock price of Optimizerx (OPRX)?
What is the market cap of Optimizerx (OPRX)?
